Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation

被引:32
作者
Jones, R
Ryan, M
Friedlander, M
机构
[1] Royal Hosp Women, Dept Gynaecol Oncol, Randwick, NSW 2031, Australia
[2] Prince Wales Childrens Hosp, Dept Med Oncol, Randwick, NSW 2031, Australia
关键词
D O I
10.1016/S0090-8258(03)00066-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. This aim of this study was to investigate the feasibility of re-treating patients who had experienced a hypersensitivity reaction to carboplatin with cisplatin following desensitisation. Methods. Five patients with recurrent ovarian cancer who had a previous documented hypersensitivity reaction to carboplatin and a good clinical indication for continuing treatment with platinum were retreated following cisplatin desensitisation. All patients were rechallenged with cisplatin following a prolonged desensitisation protocol and the initial four patients then received subsequent cycles with a shortened protocol in an attempt to simplify and shorten the procedure. Results. All five patients tolerated their first cycle of cisplatin on rechallenge using the full desensitisation protocol with no adverse reactions. Two patients received further treatments (one and three cycles) with a shortened protocol but treatment was terminated due to further adverse hypersensitivity reactions. Two patients received one further cycle with a shortened protocol and did not experience problems with hypersensitivity but treatment was stopped due to evidence of disease progression One patient received a further two cycles using the full desensitisation protocol without problems but treatment was stopped due to evidence of disease progression. Conclusions. A full cisplatin desensitisation protocol appears to be an effective way to re-treat patients who have previously experienced a hypersensitivity reaction to carboplatin. Attempts to shorten the procedure were associated with further allergic reactions, suggesting that the full protocol should be followed with each treatment. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:112 / 115
页数:4
相关论文
共 16 条
[1]   IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].
ALBERTS, DS ;
GREEN, S ;
HANNIGAN, EV ;
OTOOLE, R ;
STOCKNOVACK, D ;
ANDERSON, P ;
SURWIT, EA ;
MALVLYA, VK ;
NAHHAS, WA ;
JOLLES, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717
[2]  
Broome CB, 1996, MED PEDIATR ONCOL, V26, P105
[3]   Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy [J].
Dizon, DS ;
Sabbatini, PJ ;
Aghajanian, C ;
Hensley, ML ;
Spriggs, DR .
GYNECOLOGIC ONCOLOGY, 2002, 84 (03) :378-382
[4]   A modified, prolonged desensitization protocol in carboplatin allergy [J].
Goldberg, A ;
ConfinoCohen, R ;
Fishman, A ;
Beyth, Y ;
Altaras, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (04) :841-843
[5]   ALLERGIC REACTIONS TO CARBOPLATIN [J].
HENDRICK, AM ;
SIMMONS, D ;
CANTWELL, BMJ .
ANNALS OF ONCOLOGY, 1992, 3 (03) :239-240
[6]  
KROOK H, 1998, BONE MARROW TRANSPL, V21, P727
[7]   Clinical features of hypersensitivity reactions to carboplatin [J].
Markman, M ;
Kennedy, A ;
Webster, K ;
Elson, P ;
Peterson, G ;
Kulp, B ;
Belinson, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1141-1145
[8]   Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens [J].
Markman, M ;
Kennedy, A ;
Webster, K ;
Kulp, B ;
Peterson, G ;
Belinson, J .
GYNECOLOGIC ONCOLOGY, 1997, 65 (03) :434-436
[9]   HYPERSENSITIVITY REACTIONS TO CARBOPLATIN GIVEN TO PATIENTS WITH RELAPSED OVARIAN-CARCINOMA [J].
MORGAN, JS ;
ADAMS, M ;
MASON, MD .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1205-1206
[10]   HYPERSENSITIVITY REACTIONS TO CARBOPLATIN [J].
PLANNER, RS ;
WEERASIRI, T ;
TIMMINS, D ;
GRANT, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (23) :1763-1764